desogestrel/ethinylestradiol / Generic mfg. - LARVOL DELTA

Efficacy and safety of desogestrel/ethinylestradiol 150/20 flexible extended regimen (FREEDOM 150/20) in dysmenorrhea: phase 3 study in Japan. (PubMed, F S Rep) - "DSG/EE 150/20 effectively reduced dysmenorrhea severity, improved SF-36v2 scores and treatment satisfaction, offered dosing flexibility, and was well-tolerated with a safety profile consistent with combined oral contraceptives. jRCT2031230276 (https://jrct.mhlw.go.jp/en-latest-detail/jRCT2031230276)."

Journal • P3 data • Infectious Disease • Pain • Women's Health

EFFICACY AND SAFETY OF EFBEMALENOGRASTIM ALFA IN THE TREATMENT OF NEUTROPENIA INDUCED BY R-CHOP-LIKE REGIMENS IN NEWLY DIAGNOSED NON-HODGKIN'S LYMPHOMA PATIENTS CLINICAL STUDY (EHA 2026) - P4 | "Efbemalenograstim a is anovelong-acting G-CSF approved by FDA in 2023, but there have been no reported data on its use in newly diagnosed non-Hodgkin's lymphoma patients to date. Summary/Conclusion Using efbemalenograstim alfa for the primary prophylaxis of neutropenia induced by R-CHOP-like treatment regimens in patients with newly diagnosed non-Hodgkin's lymphoma is effective and safe. The efficacy and safety of efbemalenograstim alfa in preventing neutropenia"

Clinical • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma

Comparative adverse event reporting patterns of desogestrel versus norethisterone in third-generation combined oral contraceptives: A disproportionality analysis of the FAERS satabase. (PubMed, Medicine (Baltimore)) - "The aim was to investigate the adverse event reporting patterns of 2 commonly used combined contraceptives (desogestrel/ethinyl estradiol (DES) and norethisterone/ethinyl estradiol (NOR)) using the Food and Drug Administration Adverse Event Reporting System database. In this analysis, DES showed stronger reporting signals for arterial thrombosis, perinatal complications, and abnormal withdrawal bleeding, while NOR was more associated with vena cava thrombosis, contraceptive failure, withdrawal bleeding, and breast enlargement. Clinicians may pay particular attention to women of reproductive age, specifically those aged 18 to 40 years."

Adverse events • Clinical • Journal • Cardiovascular • Hematological Disorders • Perinatal Disorders • Thrombosis

Synthetic progestin treatment alters cytokine expression and impairs vaccine response in horses. (PubMed, Vet Immunol Immunopathol) - "When evaluating cytokines, altrenogest suppressed concentrations of IL-1β, IL-6, IL-10, and IFNγ (p < 0.01) for the duration of the study. Therefore, altrenogest impacts the antibody response to the EAV vaccine, and this may be governed by anti-cytokine function. Future research is needed to determine the clinical ramifications of this deviated antibody response."

Journal • IFNG • IL10 • IL1B • IL6

Synergistic effects of melatonin and dienogest on pain relief in endometriosis: a randomized controlled trial. (PubMed, Obstet Gynecol Sci) - "Adjunctive melatonin therapy with dienogest significantly improved dysmenorrhea compared with dienogest alone. However, the addition of melatonin did not yield significant improvements in other pain domains or quality of life indices. These results support the use of melatonin as a targeted adjunct treatment for menstrual pain during endometriosis."

Journal • Endometriosis • Gynecology • Infertility • Musculoskeletal Pain • Otorhinolaryngology • Pain • Sexual Disorders • Vertigo • Women's Health

An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Recruiting ➔ Completed

Trial completion

Uterine artery embolization versus dienogest for symptomatic adenomyosis: A randomized controlled trial of short-term efficacy. (PubMed, Eur J Radiol) - "At 6 months, UAE achieved better symptom relief and anatomical outcomes than dienogest, supporting UAE as an effective uterine-sparing therapy for symptomatic adenomyosis."

Journal • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Solid Tumor • Uterine Leiomyoma • Women's Health

Reproductive Performance of Gilts After Different Periods of Altrenogest Treatment in a Batch Farrowing Breeding Herd. (PubMed, Reprod Domest Anim) - "The duration of Altrenogest supplementation did not affect estrous cycle synchronisation efficiency or the reproductive performance of gilts. The strategic use of Altrenogest enables a reduction in labour and costs by allowing progestogen supplementation for fewer than 14 days."

Journal • Retrospective data

Eccdna-encoded LIPIN1 drives DGAT1-dependent lipid droplet biogenesis to promote Acute Myeloid Leukemia progression and chemoresistance (ASH 2025) - "This study provides preclinical evidence that eccDNA plays a critical role in AML progressionand chemoresistance by encoding LIPIN1. Mechanistically, ecc-LIPIN1 promotes lipid droplet formationand ER stress via DGAT1, ultimately driving chemoresistance. These findings identify ecc-LIPIN1 as a noveloncogenic factor in AML and highlight its potential as a therapeutic target."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Metabolic Disorders • ATF4 • LPIN1

Lactate promotes DLBCL progression via NAT10/ldha axis and immune suppression (ASH 2025) - "This study provides preclinical evidence that tumor-intrinsic lactate plays a pivotal role inDLBCL progression and immunosuppression through protein lactylation. Mechanistically, lactateincreases NAT10 protein levels via lactylation, and NAT10, in turn, promotes LDHA expression throughmRNA acetylation. LDHA further enhances lactate production, forming a positive feedback loop thatdrives tumor progression and suppresses antitumor immunity."

IO biomarker • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • CD8 • IFNG • LDHA • NAT10

Insights in the management of older adults with mantle cell lymphoma amidst a changing therapeutic landscape: Lessons from a 25-year institutional experience (ASH 2025) - "Historically,chemoimmunotherapy (CIT) with bendamustine and rituximab (BR) +/- R maintenance was the preferredfrontline (1L) treatment option in 'transplant ineligible' patients, however, this paradigm has beenchallenged with the Introduction of BTK inhibitors (BTKi). In OA, the ECHO study showed improvedprogression-free survival (PFS) of acalabrutinib-BR over BR, with acalabrutinib being continuedindefinitely till progression. More recently, the ENRICH study showed an improved PFS for ibrutinib-rituximab (IR) over R-CHOP, with similar PFS as BR in OA...PFS and OS were estimated using theKaplan-Meier method, comparisons were made using log-rank test and associations between outcomes,clinical, and tx characteristics were evaluated with Fischer exact test.ResultsIn 419 OA with MCL, median age was 72y (range 65-102y), age ≥80y 19%, male 73%, Stage 4 82%, MIPIlow/intermediate/high 6%/47%/47%, blastoid/pleiomorphic 14%, Ki67 <30%/30-49%/≥50% 49%/25%/26%,p53..."

Clinical • IO biomarker • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • TP53

An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

New P1 trial

Comparison of the short-term effects of dienogest and oral contraceptives on pain and quality of life in women with endometriosis: a systematic review and meta-analysis. (PubMed, BMC Womens Health) - "Dienogest is superior to OCPs in improving pain and QoL in patients with endometriosis, but not as effective as OCPs in pelvic pain and dyspareunia, and the safety was similar between the two types of drugs."

Clinical • HEOR • Journal • Retrospective data • Review • Back Pain • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health

Incidence of spontaneous ultrasonographic regression of the corpus luteum in pregnant embryo recipients and broodmares: a field study. (PubMed, Theriogenology) - "Progesterone or altrenogest supplementation was administered in 34 % (18/53) of cases with spontaneous luteolysis of which 44.4 % (8/18) maintained their pregnancy by Day 42. The findings highlight that spontaneous luteolysis is more prevalent than previously reported and may occur even with apparently morphologically normal embryos, suggesting that MRP failure is multifactorial and not solely linked to embryonic development. These results emphasize the need for earlier and more accurate diagnostics to identify at-risk pregnancies and guide treatment, especially in IVP derived pregnancies, which have the highest incidence of luteolysis."

Journal

Cost-effectiveness of dienogest compared to gonadotropin releasing hormone agonists for the management of endometriosis in Vietnam. (PubMed, Cost Eff Resour Alloc) - "Dienogest is a cost-effective alternative to GnRH-a drugs for treating dysmenorrhea and pelvic pain in Vietnam, offering improved health outcomes at a lower cost. These findings support its broader adoption in clinical practice and healthcare policy."

HEOR • Journal • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health

Effect of the new fixed-time artificial insemination technology based on novel hormone preparations in gilts. (PubMed, Anim Reprod Sci) - "Control gilts received oral altrenogest solution (20 mg/day) for 18 days, followed by 1000 IU equine chorionic gonadotropin (eCG) administered 42 h post-treatment and 100 μg GnRH 80 h later...Notably, the new treatment group exhibited superior litter productivity with significantly increased total born (13.81 vs. 11.80, P < 0.05) and live-born piglets (11.81 vs. 10.39, P < 0.05). These findings suggest that the new FTAI protocol achieves comparable synchronization efficacy while enhancing litter productivity compared to traditional regimens, supporting its use as an effective alternative for gilts reproductive management."

Journal

Multi center efficacy and safety of desogestrel ethinylestradiol tablets in the treatment of polycystic ovary syndrome (PCOS) Real world clinical research (ChiCTR) - P4 | N=600 | Not yet recruiting | Sponsor: Sichuan Provincial Maternal and Child Health Hospital; Sichuan Provincial Maternal and Child Health Hospital

New P4 trial • Real-world evidence • Polycystic Ovary Syndrome

SGLT2 INHIBITORS: FROM GLYCEMIC CONTROL TO CARDIO-RENAL PROTECTION EVLOEV KHARON KH1*, SNITSA DANIIL V2, PANKOV DANIL S2, GASPARYAN MARIYA A1, ZAYCEV MATVEY V3, KOIFMAN NATALYA A1, BUGLO ELENA A4, ZEFIROVA MARGARITA S2, RACHKOVA TAMARA A2, GURTIEV DMITRII A1, ZASEEVA VICTORIA V1, TOLMASOV JALOLIDDIN M1. 1NORTH-WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I.I. MECHNIKOV, SAINT-PETERSBURG,... (PubMed, Georgian Med News) - "We discuss landmark cardiovascular and renal outcome trials, evaluate the physiological and molecular mechanisms, including hemodynamic modulation, anti-inflammatory and antifibrotic effects, and improvements in myocardial and renal energetics, and assess the role of SGLT2 inhibitors in heart failure with reduced and preserved ejection fraction, as well as in chronic kidney disease with and without diabetes. The translation of these findings into clinical guidelines has reshaped therapeutic strategies in both endocrinology and cardiology, underscoring the importance of SGLT2 inhibitors as a cornerstone in cardiorenal protection."

Clinical guideline • Journal • Review • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Endocrine Disorders • Heart Failure • Metabolic Disorders • Nephrology • Pediatrics • Renal Disease • Type 2 Diabetes Mellitus

Hormonal imbalance-mediated immune inflammation in endometrial decidualization disorder. (PubMed, Placenta) - "Dienogest suppresses aromatase/cyclooxygenase-2 (COX-2)-mediated oestrogen synthesis and restores progesterone sensitivity via PR-B upregulation. Immunomodulatory approaches, including corticosteroids and tumour necrosis factor-α inhibitors, improve pregnancy outcomes in endometriosis-associated infertility. Future research, leveraging state-of-the-art technologies, should prioritise elucidating the molecular interactions within the oestrogen-progesterone-immune axis and translating these insights into personalised therapies to optimise the management of decidualization-related disorders."

Journal • Review • Endometriosis • Gynecology • Infertility • Inflammation • Oncology • Sexual Disorders • Women's Health • IL10 • PGR

CalTrig: A GUI-based Machine Learning Approach for Decoding Neuronal Calcium Transients in Freely Moving Rodents. (PubMed, eNeuro) - "Tools such as MiniAN and CalmAn have been developed to convert Ca 2+ visual signals to numerical data, collectively referred to as CalV2N...This tool's adaptability and computational efficiency support diverse research applications, from behavioral neuroscience to translational studies. In brief, CalTrig enhances the precision and scalability of Ca2+ transient analysis, paving the way for deeper exploration of neuronal dynamics and facilitating advancements in neuroscience research."

Journal • Preclinical • CNS Disorders

Deeply Infiltrating Endometriosis (DIE) No More: Dienogest as a Game Changer in Rectovaginal Endometriosis. (PubMed, Cureus) - "This is the first reported case of Dienogest successfully shrinking rectovaginal deeply infiltrating endometriosis from 3 cm to undetectable on ultrasound and vaginal examination. This case demonstrates the success of Dienogest as a therapeutic modality for rectovaginal endometriosis, highlighting its promising potential as a standard treatment approach in the long-term management of the relapsing, chronic, and debilitating nature of endometriosis."

Journal • Endometriosis • Gynecology • Women's Health

EFFICACY AND SAFETY OF EFBEMALENOGRASTIM ALFA IN THE TREATMENT OF NEUTROPENIA INDUCED BY RCHOP-LIKE REGIMENS IN NEWLY DIAGNOSED NON-HODGKIN'S LYMPHOMA PATIENTS: A RANDOMIZED CONTROLLED MULTICENTER CLINICAL STUDY (EHA 2025) - P4 | "Efbemalenograstim a is anovelong-acting G-CSF approved by FDA in 2023, but there have been no reported data on its use in newly diagnosed non-Hodgkin's lymphoma patients to date. Using efbemalenograstim alfa for the primary prophylaxis of neutropenia induced by R-CHOP-like treatment regimens in patients with newly diagnosed non-Hodgkin's lymphoma is effective and safe."

Clinical • Back Pain • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Lymphoma • Musculoskeletal Pain • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Pain

The effect of pregnancy, heat stress and altrenogest supplementation on the porcine mid-luteal phase corpus luteum proteome. (PubMed, Theriogenology) - "These included proteins involved in oxidoreductase activity (SOD1), translation and ribosomal activity, and metal ion binding (PGMRC1 and CYCS). An understanding of these effects could help improve reproductive performance in swine production."

Journal • Preclinical • MRC1

Minimally Invasive Mitral Valve Surgery Using the FlexCrown Retractor: A Safe and Effective New Self-Expandable Left Atrial Exposure Device. (PubMed, Innovations (Phila)) - "The FlexCrown self-expandable left atrial retractor by Geister allows excellent and safe exposure of the mitral valve with fast deployment and removal during MIMVS. The use of this innovative retractor may represent a helpful alternative to conventional left atrial retractors."

Journal • Cardiovascular

Medical treatment for adenomyosis: long term use of progestins. (PubMed, Gynecol Endocrinol) - "The treatment groups included dienogest (2 mg, n = 71), levonorgestrel-releasing intrauterine device (52 mg, n = 25), desogestrel (75 mcg, n = 20), and drospirenone (4 mg, n = 24)...Dienogest significantly reduced dysmenorrhea, dyspareunia, and HMB, with efficacy maintained over three years in most patients...Norethisterone acetate was used as a second-line treatment in cases of intolerance or inadequate response. Progestins are effective for the long-term management of adenomyosis symptoms. The flexibility in switching between different progestins or routes of administration may help in optimizing outcomes."

Journal • Endometriosis • Long-acting Reversible Contraceptives • Pain • Women's Health